Loading…
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $48.2B | $15.2B | $7.1B | $12.8B | 38.2% | -0.2% | -178.8% |
| 2024 | $48.3B | $3.2B | $-8.9B | $13.9B | -54.8% | 7.3% | -211.5% |
| 2023 | $45.0B | $19.4B | $8.0B | $12.7B | 27.3% | -2.5% | 26.8% |
| 2022 | $46.2B | $19.2B | $6.3B | $11.9B | 20.4% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 46,159 | 45,006 | 48,300 | 48,195 |
| Operating Revenue | - | 45,413 | 44,386 | 47,257 | 47,203 |
| Cost Of Revenue | - | 10,137 | 10,693 | 13,968 | 13,936 |
| Gross Profit | - | 36,022 | 34,313 | 34,332 | 34,259 |
| Operating Expense | - | 26,918 | 26,118 | 28,445 | 20,535 |
| Research And Development | - | 9,509 | 9,299 | 11,159 | 9,951 |
| Selling General And Administration | - | 7,814 | 7,772 | 8,414 | 7,267 |
| Total Expenses | - | 37,055 | 36,811 | 42,413 | 34,471 |
| Operating Income | - | 9,104 | 8,195 | 5,887 | 13,724 |
| EBITDA | - | 19,221 | 19,366 | 3,168 | 15,230 |
| Normalized EBITDA | - | 21,414 | 20,239 | 17,100 | 19,945 |
| EBIT | - | 8,945 | 9,606 | -6,432 | 11,219 |
| Interest Expense | - | 1,232 | 1,166 | 1,947 | 1,891 |
| Net Interest Income | - | -1,232 | -1,166 | -1,947 | -1,891 |
| Other Non Operating Income Expenses | - | 2,034 | 2,284 | 1,613 | 2,211 |
| Other Income Expense | - | -159 | 1,411 | -12,319 | -2,504 |
| Interest Expense Non Operating | - | 1,232 | 1,166 | 1,947 | 1,891 |
| Net Non Operating Interest Income Expense | - | -1,232 | -1,166 | -1,947 | -1,891 |
| Pretax Income | - | 7,713 | 8,440 | -8,379 | 9,328 |
| Tax Provision | - | 1,368 | 400 | 554 | 2,272 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -388.16 | -41.03 | -2,925.72 | -1,148.42 |
| Net Income Continuous Operations | - | 6,345 | 8,040 | -8,933 | 7,055 |
| Net Income From Continuing And Discontinued Operation | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income From Continuing Operation Net Minority Interest | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income Common Stockholders | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income Including Noncontrolling Interests | - | 6,345 | 8,040 | -8,933 | 7,055 |
| Normalized Income | - | 8,131.84 | 8,856.97 | 2,058.28 | 10,620.58 |
| Diluted NI Availto Com Stockholders | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Basic Average Shares | - | 2,130 | 2,069 | 2,027 | 2,034 |
| Diluted Average Shares | - | 2,146 | 2,078 | 2,027 | 2,039 |
| Reconciled Depreciation | - | 10,276 | 9,760 | 9,600 | 4,011 |
| Reconciled Cost Of Revenue | - | 9,456 | 9,980 | 13,240 | 13,242 |
| Total Unusual Items | - | -2,193 | -873 | -13,932 | -4,715 |
| Total Unusual Items Excluding Goodwill | - | -2,193 | -873 | -13,932 | -4,715 |
| Minority Interests | - | -18 | -15 | -15 | -2 |
| Special Income Charges | - | -1,563 | -1,162 | -14,426 | -5,225 |
| Gain On Sale Of Business | 9 | 211 | 0 | -15 | - |
| Other Special Charges | - | 444 | -390 | 84 | 434 |
| Impairment Of Capital Assets | 0 | 0 | 29 | 47 | - |
| Restructuring And Mergern Acquisition | - | 1,330 | 1,552 | 14,342 | 4,791 |
| Gain On Sale Of Security | - | -630 | 289 | 494 | 510 |
| Depreciation Amortization Depletion Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Depreciation And Amortization In Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| General And Administrative Expense | 7,675 | 7,814 | - | - | - |
| Other Gand A | 7,690 | 7,814 | - | - | - |
| Salaries And Wages | -15 | - | - | - | - |
| Selling And Marketing Expense | 7,690 | 7,814 | - | - | - |
| Earnings From Equity Interest | 745 | -801 | -160 | - | - |
| Amortization | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Amortization Of Intangibles Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Other Taxes | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Companythis co. | BMY | $115.6B | 16.39↓ discount | 6.26 | 38.2% | 10.01 |
| Pfizer Inc. | PFE | $146.4B | 18.84 | 1.69 | 9.0% | 12.47 |
| Danaher Corporation | DHR | $132.1B | 36.55 | 2.51 | 6.9% | 21.19 |
| CVS Health Corporation | CVS | $121.0B | 68.43 | 1.61 | 2.4% | 19.52 |
| Stryker Corporation | SYK | $115.5B |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 35.57 |
| 5.15 |
| 14.5% |
| 20.16 |
| Vertex Pharmaceuticals Incorporated | VRTX | $112.1B | 28.36 | 6.01 | 21.2% | 22.41 |
| Medtronic plc | MDT | $105.2B | 22.56 | 2.19 | 9.7% | 14.26 |
| McKesson Corporation | MCK | $91.0B | 19.11 | -41.89 | -219.2% | 13.32 |
| Elevance Health, Inc. | ELV | $88.9B | 15.70 | 2.03 | 12.9% | - |
| Peer Median | - | 25.46 | 2.11 | 9.3% | 19.52 | |